First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Jul 08 13:07 2019 Print This Article

Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.

The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on DrugPatentWatch - Make Better Decisions.The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants appeared first on Biotechblog.

Read More

About Article Author

Biotech Blog

  Categories:

Related Items

Ottawa postpones short-sighted drug-pricing regulations

Author: Bacchus Barua Planned changes would likely result in fewer new and innovative drugs available to Canadians. Read more about Ottawa postpones short-sighted drug-pricing regulations Tags:  pmprb pharmaceutical drugs pharmaceutical innovation prescription drug prices ...

Customer Success: Formulary Management

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentW ...

There’s still upside to Aurinia Pharma, says Mackie Research

All eyes are on a 2021 launch of voclosporin, lead candidate from drug developer Aurinia Pharmaceuticals (Aurinia Pharma Stock Quote, Chart, News NASDAQ:AUPH), but the stock received a target price trim from analyst André Uddin of Mackie Research on Friday, going from $24.00 to $22.00 per share. V ...

GW Pharmaceuticals is a world leader, AltaCorp Capital says

As the world’s first company to commercialize a plant-based cannabinoid-derived pharmaceutical, GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, Chart, News NASDAQ:GWPH) stands out as a Top Pick for 2020, according to David M. Kideckel, analyst for AltaCorp Capital, who stayed bullish on the n ...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends.  Inclusion Criteria  Our ana ...

Is it time to sell your Pfizer stock?

Is Pfizer (Pfizer Stock Quote, Chart, News NYSE:PFE) looking interesting here? With its gains over the past couple of years effectively erased now and the stock plunging big time over February, investors might think there’s value in the pharma giant. Don’t buy it, says fund manager Gordon Reid, ...

GW Pharmaceuticals keeps “Outperform” rating at AltaCorp Capital

After reporting fourth quarter earnings, GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, Chart, News NASDAQ:GWPH) has received a target reduction from AltaCorp Capital analyst David M. Kideckel, who in an update to clients on Tuesday stayed bullish on the company nonetheless. UK-based cannabino ...

Three reasons to buy Theratechnologies from Mackie Research

Mackie Research analyst André Uddin is staying bullish on specialty pharma company Theratechnologies (Theratechnologies Stock Quote, Chart, News TSX:TH) after its latest quarterly results. The analyst reviewed Theratechnologies fourth quarter in a report to clients on Tuesday and reiterated his ...

Tech Talk for Monday February 24th 2020

Pre-opening Comments for Monday February 24th Equity Index futures were lower this morning. S&P 500 futures were down 85 points to 3,259.25. Index futures responded to concerns that the coronavirus has spread beyond China. Several sectors responded strongly to rising coronavirus concerns. Gold jum ...

Acasti Pharma has price target cut at Echelon

Delays at Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) have Echelon Wealth Partners analyst Douglas Loe lowering his price target on the stock. On Monday, after finding what it said were “some unexpected and inconsistent findings that it believes may have negatively contribute ...